Oppenheimer Comments on Product Development at United Therapeutics

Oppenheimer has published a research report on United Therapeutics UTHR. In the report, Oppenheimer wrote, "UTHR will report key ph.III FREEDOM-C2 results for oral treprostinil in combination with PDE5/ERAs for PAH by the end of August. Based on FREEDOM-M/C results, we believe that oral treprostinil will likely demonstrate a significant, 15-20M 6MWD benefit. Our analyses and physician feedback indicate that this outcome, combined with FREEDOM-M, should be sufficient for oral treprostinil's approval and significant adoption." Oppenheimer rated United Therapeutics an Outperform with a price target of $77.00. United Therapeutics closed Friday at $48.77.